Skip to contents

Studies of alogliptin for lowering blood glucose concentration in patients with type II diabetes

alog_pcfb.Rd

A dataset from a systematic review of Randomised-Controlled Trials (RCTs) comparing different doses of alogliptin with placebo langford2016MBNMAtime. The systematic review was simply performed and was intended to provide data to illustrate a statistical methodology rather than for clinical inference. Alogliptin is a treatment aimed at reducing blood glucose concentration in type II diabetes. The outcome is continuous, and aggregate data responses correspond to the mean change in HbA1c from baseline to follow-up. The dataset includes 14 Randomised-Controlled Trials (RCTs), comparing 5 different doses of alogliptin with placebo, leading to 6 different treatments (combination of dose and agent) within the network.

Usage

alog_pcfb

Format

A data frame in long format (one row per arm and study), with 46 rows and 9 variables:

  • studyID Study identifiers

  • clinicaltrialGov_ID The clinicaltrial.gov ID code

  • agent Character data indicating the agent to which participants were randomised

  • dose Numeric data indicating the standardised dose received

  • treatment Character data indicating the treatment (combination of agent and dose) to which participants were randomised

  • time Numeric data indicating the time at which the observation was measured (given in weeks)

  • y Numeric data indicating the mean change from baseline in blood glucose concentration (mg/dL) in a study arm

  • se Numeric data indicating the standard error for the mean change from baseline in blood glucose concentration (mg/dL) in a study arm

  • n Numeric data indicating the number in each arm at each follow-up time

Details

alog_pcfb is a data frame in long format (one row per observation, arm and study), with the variables studyID, clinicaltrialGov_ID, agent, dose, treatment, time, y, se, and n.

References